Published in N Engl J Med on May 01, 2003
Immunogenicity of 3+1 Versus 2+1 Schedule for PCV7 | NCT02040402
U.S. hospitalizations for pneumonia after a decade of pneumococcal vaccination. N Engl J Med (2013) 6.60
Sequential multiplex PCR approach for determining capsular serotypes of Streptococcus pneumoniae isolates. J Clin Microbiol (2006) 5.95
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med (2009) 4.38
Vaccine escape recombinants emerge after pneumococcal vaccination in the United States. PLoS Pathog (2007) 3.65
Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis. Clin Microbiol Rev (2010) 3.58
Recognising serious illness in feverish young children in primary care. BMJ (2007) 3.44
Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics (2009) 3.32
CD4+ T cells mediate antibody-independent acquired immunity to pneumococcal colonization. Proc Natl Acad Sci U S A (2005) 3.30
Systematic evaluation of serotypes causing invasive pneumococcal disease among children under five: the pneumococcal global serotype project. PLoS Med (2010) 3.25
Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg Infect Dis (2008) 2.74
Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin Infect Dis (2008) 2.72
Differential effects of pneumococcal vaccines against serotypes 6A and 6C. J Infect Dis (2008) 2.70
Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog (2009) 2.69
Improving the estimation of influenza-related mortality over a seasonal baseline. Epidemiology (2012) 2.68
Population genomics of post-vaccine changes in pneumococcal epidemiology. Nat Genet (2013) 2.63
Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med (2013) 2.54
New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J (2010) 2.53
Validation of a multiplex pneumococcal serotyping assay with clinical samples. J Clin Microbiol (2006) 2.48
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands. Emerg Infect Dis (2010) 2.48
Impact of pneumococcal conjugate vaccination of infants on pneumonia and influenza hospitalization and mortality in all age groups in the United States. MBio (2011) 2.48
Pre- and postvaccination clonal compositions of invasive pneumococcal serotypes for isolates collected in the United States in 1999, 2001, and 2002. J Clin Microbiol (2006) 2.46
Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev (2005) 2.36
A trial of a 7-valent pneumococcal conjugate vaccine in HIV-infected adults. N Engl J Med (2010) 2.30
The descriptive epidemiology of Streptococcus pneumoniae and Haemophilus influenzae nasopharyngeal carriage in children and adults in Kilifi district, Kenya. Pediatr Infect Dis J (2008) 2.23
Development and validation of a fourfold multiplexed opsonization assay (MOPA4) for pneumococcal antibodies. Clin Vaccine Immunol (2006) 2.20
Phage lytic enzyme Cpl-1 as a novel antimicrobial for pneumococcal bacteremia. Infect Immun (2003) 2.06
Mechanisms of microbial traversal of the blood-brain barrier. Nat Rev Microbiol (2008) 2.04
Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol (2009) 2.01
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother (2006) 1.98
Are anticapsular antibodies the primary mechanism of protection against invasive pneumococcal disease? PLoS Med (2005) 1.97
National hospitalization trends for pediatric pneumonia and associated complications. Pediatrics (2010) 1.86
Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol (2010) 1.83
Changing epidemiology of pneumococcal meningitis after the introduction of pneumococcal conjugate vaccine in the United States. Clin Infect Dis (2008) 1.80
Rapid multiplex assay for serotyping pneumococci with monoclonal and polyclonal antibodies. J Clin Microbiol (2005) 1.79
The blp bacteriocins of Streptococcus pneumoniae mediate intraspecies competition both in vitro and in vivo. Infect Immun (2006) 1.75
Increasing hospital admissions for pneumonia, England. Emerg Infect Dis (2008) 1.72
Molecular detection methods and serotyping performed directly on clinical samples improve diagnostic sensitivity and reveal increased incidence of invasive disease by Streptococcus pneumoniae in Italian children. J Med Microbiol (2008) 1.71
Pneumococcal vaccination and otitis media in Australian Aboriginal infants: comparison of two birth cohorts before and after introduction of vaccination. BMC Pediatr (2009) 1.71
Hidden epidemic of macrolide-resistant pneumococci. Emerg Infect Dis (2005) 1.68
Characterization of biofilm matrix, degradation by DNase treatment and evidence of capsule downregulation in Streptococcus pneumoniae clinical isolates. BMC Microbiol (2008) 1.64
Sickle cell trait, hemoglobin C trait, and invasive pneumococcal disease. Epidemiology (2010) 1.63
Realtime PCR is more sensitive than multiplex PCR for diagnosis and serotyping in children with culture negative pneumococcal invasive disease. PLoS One (2010) 1.59
Disease surveillance and the academic, clinical, and public health communities. Emerg Infect Dis (2003) 1.58
Multiple colonization with S. pneumoniae before and after introduction of the seven-valent conjugated pneumococcal polysaccharide vaccine. PLoS One (2010) 1.56
Use of vaccines as probes to define disease burden. Lancet (2014) 1.56
Pneumococcal surface protein A contributes to secondary Streptococcus pneumoniae infection after influenza virus infection. J Infect Dis (2009) 1.56
Global fluoroquinolone resistance epidemiology and implictions for clinical use. Interdiscip Perspect Infect Dis (2012) 1.55
Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial. PLoS Med (2011) 1.54
Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev (2006) 1.53
Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine. Antimicrob Agents Chemother (2004) 1.53
Serotype-specific mortality from invasive Streptococcus pneumoniae disease revisited. BMC Infect Dis (2004) 1.52
Impact of more than a decade of pneumococcal conjugate vaccine use on carriage and invasive potential in Native American communities. J Infect Dis (2011) 1.51
One-step multiplex PCR assay for detecting Streptococcus pneumoniae serogroups/types covered by 13-valent pneumococcal conjugate vaccine (PCV13). PLoS One (2012) 1.51
Distribution and invasiveness of Streptococcus pneumoniae serotypes in Switzerland, a country with low antibiotic selection pressure, from 2001 to 2004. J Clin Microbiol (2006) 1.51
Carriage of Streptococcus pneumoniae 3 years after start of vaccination program, the Netherlands. Emerg Infect Dis (2011) 1.49
Single-step capsular transformation and acquisition of penicillin resistance in Streptococcus pneumoniae. J Bacteriol (2004) 1.48
Glycolytic enzymes associated with the cell surface of Streptococcus pneumoniae are antigenic in humans and elicit protective immune responses in the mouse. Clin Exp Immunol (2004) 1.47
A longitudinal study of Streptococcus pneumoniae carriage in a cohort of infants and their mothers on the Thailand-Myanmar border. PLoS One (2012) 1.47
Changes in serotypes and antimicrobial susceptibility of invasive Streptococcus pneumoniae strains in Cleveland: a quarter century of experience. J Clin Microbiol (2008) 1.45
Vaccines to prevent pneumonia and improve child survival. Bull World Health Organ (2008) 1.44
Pneumococcal genome sequencing tracks a vaccine escape variant formed through a multi-fragment recombination event. Nat Genet (2012) 1.43
The burden of invasive pneumococcal disease in children with underlying risk factors in North America and Europe. Int J Clin Pract (2013) 1.43
The effect of Haemophilus influenzae type b and pneumococcal conjugate vaccines on childhood pneumonia incidence, severe morbidity and mortality. Int J Epidemiol (2010) 1.43
Molecular epidemiology of multiresistant Streptococcus pneumoniae with both erm(B)- and mef(A)-mediated macrolide resistance. J Clin Microbiol (2004) 1.43
Strain characteristics of Streptococcus pneumoniae carriage and invasive disease isolates during a cluster-randomized clinical trial of the 7-valent pneumococcal conjugate vaccine. J Infect Dis (2007) 1.43
Linking surveillance to action: incorporation of real-time regional data into a medical decision rule. J Am Med Inform Assoc (2007) 1.42
Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr (2010) 1.41
Pneumococcal carriage and antibiotic resistance in young children before 13-valent conjugate vaccine. Pediatr Infect Dis J (2012) 1.41
Characterization of the genetic lineages responsible for pneumococcal invasive disease in Portugal. J Clin Microbiol (2005) 1.37
The presence of the pilus locus is a clonal property among pneumococcal invasive isolates. BMC Microbiol (2008) 1.36
Population snapshot of Streptococcus pneumoniae serotype 19A isolates before and after introduction of seven-valent pneumococcal Vaccination for French children. J Clin Microbiol (2008) 1.36
International Circumpolar Surveillance System for invasive pneumococcal disease, 1999-2005. Emerg Infect Dis (2008) 1.34
Impact of pneumococcal conjugate vaccination on otitis media: a systematic review. Clin Infect Dis (2012) 1.33
Socioeconomic and racial/ethnic disparities in the incidence of bacteremic pneumonia among US adults. Am J Public Health (2010) 1.33
Streptococcus pneumoniae capsular serotype 19F is more resistant to C3 deposition and less sensitive to opsonophagocytosis than serotype 6B. Infect Immun (2008) 1.33
Pediatric invasive pneumococcal disease in the United States in the era of pneumococcal conjugate vaccines. Clin Microbiol Rev (2012) 1.31
Genome evolution driven by host adaptations results in a more virulent and antimicrobial-resistant Streptococcus pneumoniae serotype 14. BMC Genomics (2009) 1.31
Enhanced determination of Streptococcus pneumoniae serotypes associated with invasive disease in Laos by using a real-time polymerase chain reaction serotyping assay with cerebrospinal fluid. Am J Trop Med Hyg (2010) 1.30
In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002. Antimicrob Agents Chemother (2004) 1.30
Bacterial pneumonia and pandemic influenza planning. Emerg Infect Dis (2008) 1.30
An increase in the burden of neonatal admissions to a rural district hospital in Kenya over 19 years. BMC Public Health (2010) 1.29
Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis (2012) 1.29
Incorporation of real-time PCR into routine public health surveillance of culture negative bacterial meningitis in São Paulo, Brazil. PLoS One (2011) 1.28
Community prescribing and resistant Streptococcus pneumoniae. Emerg Infect Dis (2005) 1.27
Trends in Haemophilus influenzae type b infections in adults in England and Wales: surveillance study. BMJ (2004) 1.27
Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol (2010) 1.25
Somatic hypermutation and diverse immunoglobulin gene usage in the human antibody response to the capsular polysaccharide of Streptococcus pneumoniae Type 6B. Infect Immun (2004) 1.24
Influenza-related mortality among adults aged 25-54 years with AIDS in South Africa and the United States of America. Clin Infect Dis (2012) 1.24
S. pneumoniae transmission according to inclusion in conjugate vaccines: Bayesian analysis of a longitudinal follow-up in schools. BMC Infect Dis (2006) 1.23
Pneumococcal serotypes in children in 4 European countries. Emerg Infect Dis (2010) 1.22
Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae. Infect Immun (2005) 1.22
Population-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev (2014) 1.21
The pneumococcus: epidemiology, microbiology, and pathogenesis. Cold Spring Harb Perspect Med (2013) 1.21
Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain. Emerg Infect Dis (2009) 1.19
Identification of invasive serotype 1 pneumococcal isolates that express nonhemolytic pneumolysin. J Clin Microbiol (2006) 1.18
Molecular epidemiology of pediatric pneumococcal empyema from 2001 to 2007 in Utah. J Clin Microbiol (2009) 1.16
Serotype-specific and age-dependent generation of pneumococcal polysaccharide-specific memory B-cell and antibody responses to immunization with a pneumococcal conjugate vaccine. Clin Vaccine Immunol (2007) 1.16
Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark. PLoS One (2013) 1.15
Multiplex PCR for identification of seven Streptococcus pneumoniae serotypes targeted by a 7-valent conjugate vaccine. J Clin Microbiol (2005) 1.15
Denmark14-230 clone as an increasing cause of pneumococcal infection in Portugal within a background of diverse serotype 19A lineages. J Clin Microbiol (2009) 1.15
Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA (2007) 26.98
Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med (2005) 12.75
Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA (2003) 12.04
Multistate point-prevalence survey of health care-associated infections. N Engl J Med (2014) 8.78
Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis (2010) 8.37
Burden of Clostridium difficile infection in the United States. N Engl J Med (2015) 8.17
Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae. N Engl J Med (2006) 7.68
Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep (2002) 6.51
Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J Infect Dis (2007) 6.45
Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA (2008) 6.13
Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA (2010) 5.94
Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis (2011) 5.58
Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study. Lancet (2006) 5.56
FoodNet estimate of the burden of illness caused by nontyphoidal Salmonella infections in the United States. Clin Infect Dis (2004) 5.53
The epidemiology of invasive group A streptococcal infection and potential vaccine implications: United States, 2000-2004. Clin Infect Dis (2007) 5.36
Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA (2005) 5.29
A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol (2005) 5.26
Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis (2002) 5.23
Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J Infect Dis (2008) 4.91
A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neonates. N Engl J Med (2002) 4.88
Health care-associated invasive MRSA infections, 2005-2008. JAMA (2010) 4.79
Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol (2004) 4.51
Evaluation and improvement of real-time PCR assays targeting lytA, ply, and psaA genes for detection of pneumococcal DNA. J Clin Microbiol (2007) 4.44
Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med (2009) 4.38
National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med (2013) 4.21
Epidemiology of invasive group a streptococcus disease in the United States, 1995-1999. Clin Infect Dis (2002) 4.08
Accuracy of phenotypic and genotypic testing for identification of Streptococcus pneumoniae and description of Streptococcus pseudopneumoniae sp. nov. J Clin Microbiol (2004) 3.96
Automatic electronic laboratory-based reporting of notifiable infectious diseases at a large health system. Emerg Infect Dis (2002) 3.88
Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr (2004) 3.86
Salmonellosis outcomes differ substantially by serotype. J Infect Dis (2008) 3.77
Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J Infect Dis (2005) 3.76
Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis (2010) 3.61
Geographic diversity and temporal trends of antimicrobial resistance in Streptococcus pneumoniae in the United States. Nat Med (2003) 3.54
Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009-April 2010). Clin Infect Dis (2011) 3.46
Multilocus sequence typing as a replacement for serotyping in Salmonella enterica. PLoS Pathog (2012) 3.37